A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia

Phase III DIALIZE study (n=196 with pre-dialysis hyperkalaemia) reports 41.2% of patients who received sodium zirconium cyclosilicate (SZC) on non-dialysis days achieved normal potassium levels (4-5 mmol/L) vs 1.0% of patients receiving placebo during a 4-week period.